|
1
|
Shain AH and Bastian BC: From melanocytes
to melanomas. Nat Rev Cancer. 16:345–358. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Davis LE, Shalin SC and Tackett AJ:
Current state of melanoma diagnosis and treatment. Cancer Biol
Ther. 20:1366–1379. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rodriguez-Cerdeira C, Carnero Gregorio M,
Lopez-Barcenas A, Sánchez-Blanco E, Sánchez-Blanco B, Fabbrocini G,
Bardhi B, Sinani A and Guzman RA: Advances in immunotherapy for
melanoma: A comprehensive review. Mediators Inflamm.
2017:32642172017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Domingues B, Lopes JM, Soares P and Populo
H: Melanoma treatment in review. Immunotargets Ther. 7:35–49. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weiss SA, Wolchok JD and Sznol M:
Immunotherapy of melanoma: Facts and hopes. Clin Cancer Res.
25:5191–5201. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bhandaru M and Rotte A: Monoclonal
antibodies for the treatment of melanoma: Present and future
strategies. Methods Mol Biol. 1904:83–108. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kozar I, Margue C, Rothengatter S, Haan C
and Kreis S: Many ways to resistance: How melanoma cells evade
targeted therapies. Biochim Biophys Acta Rev Cancer. 1871:313–322.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lugowska I, Teterycz P and Rutkowski P:
Immunotherapy of melanoma. Contemp Oncol (Pozn). 22:61–67.
2018.PubMed/NCBI
|
|
10
|
Paluncic J, Kovacevic Z, Jansson PJ,
Kalinowski D, Merlot AM, Huang ML, Lok HC, Sahni S, Lane DJ and
Richardson DR: Roads to melanoma: Key pathways and emerging players
in melanoma progression and oncogenic signaling. Biochim Biophys
Acta. 1863:770–784. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Haluska FG, Tsao H, Wu H, Haluska FS,
Lazar A and Goel V: Genetic alterations in signaling pathways in
melanoma. Clin Cancer Res. 12:2301s–2307s. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y and Chen Z: Mutation detection and
molecular targeted tumor therapies. STEMedicine. 1:e112020.
View Article : Google Scholar
|
|
13
|
Mehnert JM and Kluger HM: Driver mutations
in melanoma: Lessons learned from bench-to-bedside studies. Curr
Oncol Rep. 14:449–457. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Savoia P, Fava P, Casoni F and Cremona O:
Targeting the ERK signaling pathway in melanoma. Int J Mol Sci.
20:14832019. View Article : Google Scholar
|
|
15
|
Fujimura T, Fujisawa Y, Kambayashi Y and
Aiba S: Significance of BRAF kinase inhibitors for melanoma
treatment: From bench to bedside. Cancers (Basel). 11:13422019.
View Article : Google Scholar
|
|
16
|
Luebker SA and Koepsell SA: Diverse
mechanisms of BRAF inhibitor resistance in melanoma identified in
clinical and preclinical studies. Front Oncol. 9:2682019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Johnson DB, Menzies AM, Zimmer L, Eroglu
Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, et al:
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of
the spectrum and frequencies, clinical behaviour, and phenotypic
associations of resistance mechanisms. Eur J Cancer. 51:2792–2799.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma S, Meng Z, Chen R and Guan KL: The
hippo pathway: Biology and pathophysiology. Annu Rev Biochem.
88:577–604. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim MK, Jang JW and Bae SC: DNA binding
partners of YAP/TAZ. BMB Rep. 51:126–133. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Moroishi T, Hansen CG and Guan KL: The
emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 15:73–79.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zanconato F, Cordenonsi M and Piccolo S:
YAP/TAZ at the roots of cancer. Cancer Cell. 29:783–803. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xiong H, Yu Q, Gong Y, Chen W, Tong Y,
Wang Y, Xu H and Shi Y: Yes-Associated protein (YAP) promotes
tumorigenesis in melanoma cells through stimulation of low-density
lipoprotein receptor-related protein 1 (LRP1). Sci Rep.
7:155282017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nallet-Staub F, Marsaud V, Li L, Gilbert
C, Dodier S, Bataille V, Sudol M, Herlyn M and Mauviel A:
Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in
cutaneous melanoma. J Invest Dermatol. 134:123–132. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fisher ML, Grun D, Adhikary G, Xu W and
Eckert RL: Inhibition of YAP function overcomes BRAF inhibitor
resistance in melanoma cancer stem cells. Oncotarget.
8:110257–110272. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin L, Sabnis AJ, Chan E, Olivas V, Cade
L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, et al: The Hippo
effector YAP promotes resistance to RAF- and MEK-targeted cancer
therapies. Nat Genet. 47:250–256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Meng Z, Moroishi T and Guan KL: Mechanisms
of Hippo pathway regulation. Genes Dev. 30:1–17. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yan F, Qian M, He Q, Zhu H and Yang B: The
posttranslational modifications of Hippo-YAP pathway in cancer.
Biochim Biophys Acta Gen Subj. 1864:1293972020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao B, Li L, Tumaneng K, Wang CY and Guan
KL: A coordinated phosphorylation by Lats and CK1 regulates YAP
stability through SCF (beta-TRCP). Genes Dev. 24:72–85. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tu K, Yang W, Li C, Zheng X, Lu Z, Guo C,
Yao Y and Liu Q: Fbxw7 is an independent prognostic marker and
induces apoptosis and growth arrest by regulating YAP abundance in
hepatocellular carcinoma. Mol Cancer. 13:1102014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yao F, Zhou Z, Kim J, Hang Q, Xiao Z, Ton
BN, Chang L, Liu N, Zeng L, Wang W, et al: SKP2- and
OTUD1-regulated non-proteolytic ubiquitination of YAP promotes YAP
nuclear localization and activity. Nat Commun. 9:22692018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tiscornia G, Singer O and Verma IM:
Production and purification of lentiviral vectors. Nat Protoc.
1:241–245. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Han B, Sun Y, Yang D, Zhang H, Mo S, Chen
X, Lu H, Mao X and Hu J: USP22 promotes development of lung
adenocarcinoma through ubiquitination and immunosuppression. Aging
(Albany NY). 12:6990–7005. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schrecengost RS, Dean JL, Goodwin JF,
Schiewer MJ, Urban MW, Stanek TJ, Sussman RT, Hicks JL, Birbe RC,
Draganova-Tacheva RA, et al: USP22 regulates oncogenic signaling
pathways to drive lethal cancer progression. Cancer Res.
74:272–286. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang X, Zang H, Luo Y, Wu J, Fang Z, Zhu W
and Li Y: High expression of USP22 predicts poor prognosis and
advanced clinicopathological features in solid tumors: A
meta-analysis. Onco Targets Ther. 11:3035–3046. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McCann JJ, Vasilevskaya IA, Poudel Neupane
N, Shafi AA, McNair C, Dylgjeri E, Mandigo AC, Schiewer MJ,
Schrecengost RS, Gallagher P, et al: USP22 functions as an
oncogenic driver in prostate cancer by regulating cell
proliferation and DNA repair. Cancer Res. 80:430–443. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Luise C, Capra M, Donzelli M, Mazzarol G,
Jodice MG, Nuciforo P, Viale G, Di Fiore PP and Confalonieri S: An
atlas of altered expression of deubiquitinating enzymes in human
cancer. PLoS One. 6:e158912011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang X, Tang JZ, Vergara IA, Zhang Y,
Szeto P, Yang L, Mintoff C, Colebatch A, McIntosh L, Mitchell KA,
et al: Somatic hypermutation of the YAP oncogene in a human
cutaneous melanoma. Mol Cancer Res. 17:1435–1449. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Komander D, Clague MJ and Urbe S: Breaking
the chains: Structure and function of the deubiquitinases. Nat Rev
Mol Cell Biol. 10:550–563. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Melo-Cardenas J, Zhang Y, Zhang DD and
Fang D: Ubiquitin-specific peptidase 22 functions and its
involvement in disease. Oncotarget. 7:44848–44856. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yu FX, Zhao B, Panupinthu N, Jewell JL,
Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, et al:
Regulation of the Hippo-YAP pathway by G-protein-coupled receptor
signaling. Cell. 150:780–791. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim
J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP
oncoprotein by the Hippo pathway is involved in cell contact
inhibition and tissue growth control. Genes Dev. 21:2747–2761.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nijman SM, Luna-Vargas MP, Velds A,
Brummelkamp TR, Dirac AM, Sixma TK and Bernards R: A genomic and
functional inventory of deubiquitinating enzymes. Cell.
123:773–786. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Reyes-Turcu FE, Ventii KH and Wilkinson
KD: Regulation and cellular roles of ubiquitin-specific
deubiquitinating enzymes. Annu Rev Biochem. 78:363–397. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu L, Yin S, Brobbey C and Gan W:
Ubiquitination in cancer stem cell: Roles and targeted cancer
therapy. STEMedicine. 1:e372020. View Article : Google Scholar
|
|
46
|
Samara NL, Datta AB, Berndsen CE, Zhang X,
Yao T, Cohen RE and Wolberger C: Structural insights into the
assembly and function of the SAGA deubiquitinating module. Science.
328:1025–1029. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhao Y, Lang G, Ito S, Bonnet J, Metzger
E, Sawatsubashi S, Suzuki E, Le Guezennec X, Stunnenberg HG,
Krasnov A, et al: A TFTC/STAGA module mediates histone H2A and H2B
deubiquitination, coactivates nuclear receptors, and counteracts
heterochromatin silencing. Mol Cell. 29:92–101. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Atanassov BS, Evrard YA, Multani AS, Zhang
Z, Tora L, Devys D, Chang S and Dent SY: Gcn5 and SAGA regulate
shelterin protein turnover and telomere maintenance. Mol Cell.
35:352–364. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ning J, Zhang J, Liu W, Lang Y, Xue Y and
Xu S: Overexpression of ubiquitin-specific protease 22 predicts
poor survival in patients with early-stage non-small cell lung
cancer. Eur J Histochem. 56:e462012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tang B, Liang X, Tang F, Zhang J, Zeng S,
Jin S, Zhou L, Kudo Y and Qi G: Expression of USP22 and Survivin is
an indicator of malignant behavior in hepatocellular carcinoma. Int
J Oncol. 47:2208–2216. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ning Z, Wang A, Liang J, Xie Y, Liu J,
Feng L, Yan Q and Wang Z: USP22 promotes the G1/S phase transition
by upregulating FoxM1 expression via beta-catenin nuclear
localization and is associated with poor prognosis in stage II
pancreatic ductal adenocarcinoma. Int J Oncol. 45:1594–1608. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Dai W, Yao Y, Zhou Q and Sun CF:
Ubiquitin-specific peptidase 22, a histone deubiquitinating enzyme,
is a novel poor prognostic factor for salivary adenoid cystic
carcinoma. PLoS One. 9:e871482014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Huang X, Zhang Q, Lou Y, Wang J, Zhao X,
Wang L, Zhang X, Li S, Zhao Y, Chen Q, et al: USP22 Deubiquitinates
CD274 to suppress anticancer immunity. Cancer Immunol Res.
7:1580–1590. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang L, Shi S, Guo Z, Zhang X, Han S, Yang
A, Wen W and Zhu Q: Overexpression of YAP and TAZ is an independent
predictor of prognosis in colorectal cancer and related to the
proliferation and metastasis of colon cancer cells. PLoS One.
8:e655392013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lee CK, Jeong SH, Jang C, Bae H, Kim YH,
Park I, Kim SK and Koh GY: Tumor metastasis to lymph nodes requires
YAP-dependent metabolic adaptation. Science. 363:644–649. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Rozengurt E, Sinnett-Smith J and Eibl G:
Yes-associated protein (YAP) in pancreatic cancer: At the epicenter
of a targetable signaling network associated with patient survival.
Signal Transduct Target Ther. 3:112018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Uhlen M, Fagerberg L, Hallstrom BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Xiong J, Che X, Li X, Yu H, Gong Z and Li
W: Cloning and characterization of the human USP22 gene promoter.
PLoS One. 7:e527162012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Xiong J, Zhou X, Gong Z, Wang T, Zhang C,
Xu X, Liu J and Li W: PKA/CREB regulates the constitutive promoter
activity of the USP22 gene. Oncol Rep. 33:1505–1511. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Armour SM, Bennett EJ, Braun CR, Zhang XY,
McMahon SB, Gygi SP, Harper JW and Sinclair DA: A high-confidence
interaction map identifies SIRT1 as a mediator of acetylation of
USP22 and the SAGA coactivator complex. Mol Cell Biol.
33:1487–1502. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Lin Z, Tan C, Qiu Q, Kong S, Yang H, Zhao
F, Liu Z, Li J, Kong Q, Gao B, et al: Ubiquitin-specific protease
22 is a deubiquitinase of CCNB1. Cell Discov. 1:150282015.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Manzano JL, Layos L, Buges C, de Los
Llanos Gil M, Vila L, Martínez-Balibrea E and Martínez-Cardús A:
Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl
Med. 4:2372016. View Article : Google Scholar : PubMed/NCBI
|
